For over a century, scientists have chased the dream of insulin pills, but the digestive system kept destroying the drug ...

Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Steve Ledger, ...

Chugai receives Japanese approval for Lunsumio & Polivy combo therapy for additional indication of relapsed or refractory large B-cell lymphoma: Tokyo Tuesday, March 24, 2026, 11: ...

A long-held dream in medicine is nearing reality as researchers at Kumamoto University have successfully developed insulin ...

A randomized trial finds weekly extended-release buprenorphine yields neonatal outcomes comparable to sublingual treatment.

Research reveals an innovative insulin pill that successfully delivers insulin orally, improving treatment options for ...

Protagonist's pipeline leverages its proprietary Vectrix platform to target obesity, hematology, and inflammation. Find out ...

Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo ...

Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo ...

Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoidApproval in ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...